Made available in DSpace on 2015-04-14T13:35:42Z (GMT). No. of bitstreams: 1 449039.pdf: 2035926 bytes, checksum: 76ba03094b12ab30e63451e8308ea5c3 (MD5) Previous issue date: 2013-03-21 / Objectives: to evaluate the association between brachial artery Flow Mediated Dilatation (FMD) and preeclampsia morbidity. Methods: Sixty-four pregnant women at the diagnosis of preeclampsia were selected. FMD and routine preeclampsia markers were assessed at enrollment and followed until delivery. Women were grouped and compared according to their outcomes (26 developed complications and 38 did not). Results: Median FMD is impaired in women with complicated preeclampsia (7.44%; IQR 2.20-13.34%) compared to those without complications (11.80%; IQR 5.36-16.66%) (p=0,03). The cutoff value of FMD ≤4.5% was associated with approximately four-fold odds increment of any complication (OR 3.79; IC95% 1.23-11.70), similar to the protein to creatinine ratio >2,0 (OR 4.50; IC95% 1.21-16.74). Systolic and diastolic blood pressure were not associated with risk for complication and uric acid had a borderline significance (OR 3.38; IC95% 0,98-11,72). Moreover, when major complications (eclampsia, HELLP syndrome or stillbirth) were selected as a composite outcome FMD was even lower (2.84%; IQR 0.00 7.22%) and FMD ≤4.5% was associated with a marked 15 fold increased risk for these specific events (OR 15.55; IC95% 3.55-68.16). Although FMD seems to have a weak accuracy to predict any preeclampsia complications (AUC=0.66; IC95% 0.52-0.79), ROC curve analysis showed that it may be a prognostic marker for major complications (AUC=0.84; IC95% 0.73-0.96). Conclusion: FMD is associated with morbidity of preeclampsia, markedly in women with eclampsia, HELLP syndrome or stillbirth. FMD at preeclampsia diagnostic moment may be used as a prognostic marker of these poor outcomes. / Objetivos: avaliar a associa??o entre a Dilata??o Mediada por Fluxo (DMF) da art?ria braquial e morbidade por pr?-ecl?mpsia. M?todos: Foram selecionados sessenta e quatro gr?vidas com pr?-ecl?mpsia. A DMF e marcadores de pr?-ecl?mpsia foram avaliados no no momento do diagn?stico da doen?a a as pacientes foram seguidas at? o parto. As mulheres foram agrupados e comparadas de acordo com os seus desfechos (26 com complica??es e 38 sem complica??o). Resultados: A DMF est? comprometida em mulheres com pr?-ecl?mpsia complicada (7,44%; IQR 2,20-13,34%) comparada com aqueles sem complica??es (11,80%; IQR 5,36- 16,66%) (p = 0,03). O valor de corte de DMF ≤ 4,5% foi associada com aproximadamente quatro vezes mais risco de qualquer complica??o (OR 3,79 IC95% 1,23-11,70), semelhante ? rela??o prote?na/creatinina > 2,0 (OR 4,50 IC95% 1,21-16,74). Press?o arterial sist?lica e diast?lica n?o foram associados com risco de complica??o e o ?cido ?rico teve uma signific?ncia lim?trofe (OR 3,38, IC95% 0,98-11,72). Al?m disso, quando as principais complica??es (ecl?mpsia, s?ndrome HELLP ou morte fetal) foram selecionadas como um desfecho composto a DMF foi ainda mais baixa (2,84%; IQR 0,00-7,22%) e o valor da DMF ≤ 4,5% foi associado com um acentuado aumento de 15 vezes no risco destes eventos espec?fico (OR 15,55; IC95% 3,55-68,16). Embora a DMF tenha pouca capacidade de predi??o de quaisquer complica??es pela pr?-ecl?mpsia (AUC = 0,66, IC95% 0,52-0,79), an?lise da curva ROC mostrou que pode ser um bom marcador de progn?stico para complica??es graves (AUC = 0,84, IC95% 0,73-0,96). Conclus?o: a DMF est? associada com morbidade da pr?-ecl?mpsia, notadamente em mulheres com ecl?mpsia, s?ndrome HELLP ou morte fetal. DMF no momento do diagn?stico da pr?-ecl?mpsia pode ser usado como marcador progn?stico destes desfechos desfavor?veis.